1330277-66-1

1330277-66-1结构式
1330277-66-1结构式
  • 常用中文名:(S)-10-Hydroxycamptothecin-d5
  • 常用英文名:(S)-10-Hydroxycamptothecin-d5
  • CAS号:1330277-66-1
  • 分子式:C20H11D5N2O5
  • 分子量:369.38
  • 相关类别: 信号通路 细胞凋亡 细胞凋亡
  • 发布时间:2021-10-07 18:56:52
  • 更新时间:2024-04-03 19:23:20
  • (S) -10-羟基喜树碱-d5(10-HCPT-d5)是氘标记的(S)-10-羟基喜树碱。(S) -10-羟基喜树碱(10-HCPT)是一种DNA拓扑异构酶I抑制剂。(S) -10-羟基喜树碱具有显著的凋亡诱导作用。(S) -10-羟基喜树碱有可能用于肝癌、胃癌、结肠癌和白血病研究[1][2][3][4]。

化源商城直购

中文名 (S)-10-羟基喜树碱 d5
英文名 (S)-10-Hydroxycamptothecin-d5
描述 (S) -10-羟基喜树碱-d5(10-HCPT-d5)是氘标记的(S)-10-羟基喜树碱。(S) -10-羟基喜树碱(10-HCPT)是一种DNA拓扑异构酶I抑制剂。(S) -10-羟基喜树碱具有显著的凋亡诱导作用。(S) -10-羟基喜树碱有可能用于肝癌、胃癌、结肠癌和白血病研究[1][2][3][4]。
相关类别
体外研究 氢、碳和其他元素的稳定重同位素已被纳入药物分子,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
参考文献

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecinwith targeted nanostructured lipid carriers againstmultidrug resistance. Journal of Drug Targeting.

[3]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targetednanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8

[4]. Yu P, et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol Pharm Bull. 2012;35(8):1295-9.

[5]. Zhang XW, et al. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin. 2000 Apr;21(4):364-8.

[6]. Zhang XW, et al. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs. 2000 Oct;11(9):747-56.

[7]. Liu M, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24(5):433-40.

分子式 C20H11D5N2O5
分子量 369.38
储存条件 -20°C,干燥,密封